![](/img/cover-not-exists.png)
No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
Harvey, Philip D, Sabbagh, Marwan N, Harrison, John E, Ginsberg, Henry N, Chapman, M John, Manvelian, Garen, Moryusef, Angele, Mandel, Jonas, Farnier, MichelVolume:
39
Language:
english
Journal:
European Heart Journal
DOI:
10.1093/eurheartj/ehx661
Date:
February, 2018
File:
PDF, 655 KB
english, 2018